Objectives
The Genomics Unit specializes in genomics analyses for R&D, ocusing on identifying gene mutations to enhance the diagnosis and the treatment of cancer and infectious diseases.
The Genomics Unit provides accredited genomics tests for clinical trials and enables researchers to investigate current challenges and solutions confronting surveillance specialists and modelers who work with genomic data.
Areas of impact and applications in the field
Cancer cells have advantages over normal cells in selective growth and survival in the context of cancer, and genomic alterations are the root of those advantages. The genomic landscapes for the most prevalent types of human cancer have been revealed over the past ten years, particularly with next-generation sequencing (NGS) technologies, also known as second-generation, in the mid-2000s. These discoveries have assisted in the early detection, prognosis, and treatment of tumors.
The Genomics Unit will require advanced computational biology efforts to identify novel biomarkers in cancer research. These endeavors will contribute to a better understanding of what genomics-based cancer theranostics has accomplished, as well as its prospects and limitations.
Genomic technologies have also led to tremendous gains in understanding how pathogens function, evolve and interact in infectious diseases. Because sequencing methods have improved in speed and capacity over the past ten years, at a decreased cost, pathogen diversity can now be measured with great precision and resolution.
Services
- NGS WGS QIAseqFX kit
- Accredited Services
- Mutation Analysis of Single-Gene Disorders by Next-Generation Sequencing (NGS) (KRAS, NRAS, EGFR, BRAF)
- FISH (ALK)
